Goldman Sachs
CRVO icon

Goldman Sachs’s CervoMed CRVO Stock Holding History

Goldman Sachs’s Portfolio CRVO Stock Details CRVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-21,199
Closed -$133K – 6382
2025
Q2 		$133K Buy
+21,199
New +$181K ﹤0.01% 5761
2025
Q1 		– Sell
-13,750
Closed -$32.2K – 6119
2024
Q4 		$32.2K Buy
+13,750
New +$134K ﹤0.01% 5868
2020
Q4 		– Sell
-1,308
Closed -$83K – 5515
2020
Q3 		$83K Buy
+1,308
New +$99.4K ﹤0.01% 5119
2018
Q4 		– Sell
-57
Closed -$28K – 5292
2018
Q3 		$28K Buy
+57
New +$26.5K ﹤0.01% 5381
2017
Q4 		– Sell
-20
Closed -$37K – 6383
2017
Q3 		$37K Buy
+20
New +$41.4K ﹤0.01% 6322
2017
Q2 		– Sell
-14
Closed -$61K – 6786
2017
Q1 		$61K Buy
+14
New +$60.1K ﹤0.01% 6232

Other funds holding CRVO

AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CFG
Citizens Financial Group Providence, Rhode Island $7.19B AUM 23.93% 1-Year Est. Return
PWM
Perigon Wealth Management San Francisco, California $5.51B AUM 24.51% 1-Year Est. Return
Cetera Investment Advisers
Cetera Investment Advisers Schaumburg, Illinois $94B AUM 20.14% 1-Year Est. Return

Goldman Sachs's CRVO Position: Q3 2025 in Review

Goldman Sachs sold out of CervoMed (CRVO) in Q3 2025, closing a stake of 21,199 shares — an estimated $133K sold.

Goldman Sachs first reported a position in CRVO in Q1 2017 and held it in 6 quarters. The position peaked at $133K in Q2 2025. 45 funds tracked by Wall St. Rank hold CRVO as of Q3 2025.

  • Goldman Sachs reported no remaining CervoMed position as of Q3 2025 after selling out during the quarter.
  • Goldman Sachs sold 21,199 CervoMed shares in Q3 2025, an estimated $133K.
  • Goldman Sachs first reported a position in CervoMed in Q1 2017 and held it in 6 quarters.
  • Goldman Sachs's CervoMed position peaked at $133K in Q2 2025.
  • 45 funds tracked by Wall St. Rank held CervoMed as of Q3 2025.

Based on Goldman Sachs's 13F filing for Q3 2025, filed 14 Nov 2025.